NCT04645121View on ClinicalTrials.gov

Carbon Monoxide-based Rebreathing Method and Bioimpedance in Hemodialysis Patients

CompletedOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

November 25, 2020

Primary Completion Date

May 20, 2022

Study Completion Date

June 1, 2022

Conditions
Hemodialysis ComplicationVolume Overload
Interventions
DEVICE

Carbon Monoxide-based Rebreathing

6 minutes Carbon Monoxide-based Rebreathing that estimate blood volume, plasma volume and erythrocyte volume.

DEVICE

Bioimpedance

Measures total volume, intra and extracellular volume.

RADIATION

Radioactive labelling of erythrocytes and albumin

Measure blood volume, plasma volume and erythrocyte volume.

Trial Locations (2)

2100

Herlev Hospital, Copenhagen

Rigshospitalet, Department of Nephrology, København Ø

All Listed Sponsors
collaborator

Herlev Hospital

OTHER

lead

Rigshospitalet, Denmark

OTHER

NCT04645121 - Carbon Monoxide-based Rebreathing Method and Bioimpedance in Hemodialysis Patients | Biotech Hunter | Biotech Hunter